Latest Sublingual administration Stories
In an examination of a type of treatment for allergic rhinitis and asthma that is used in Europe but not approved by the U.S. Food and Drug Administration, researchers found moderate strength in the evidence from previous studies to support the use of sublingual immunotherapy for the treatment of these conditions, according to an article in the March 27 issue of JAMA. Sublingual immunotherapy involves administration of aqueous allergens under the tongue for local absorption to desensitize the...
APS Pharmacy announced today that it is now offering Sublingual Immunotherapy (SLIT) for allergy patients. Sublingual Immunotherapy (SLIT) is a method of treating allergies by desensitizing individuals to allergens with sublingual drops. Palm Harbor, FL (PRWEB) December 22, 2012 APS Pharmacy announced today that it is now offering Sublingual Immunotherapy (SLIT) for allergy patients. Sublingual Immunotherapy (SLIT) is a method of treating allergies by desensitizing individuals to...
REDWOOD CITY, Calif., April 11, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Patent and Trademark Office (USPTO) has issued AcelRx two Notices of Allowance for the patent applications entitled "Small-Volume Oral Transmucosal Dosage Forms" and "Bioadhesive Drug Formulations for Oral...
PHOENIX, Jan. 4, 2012 /PRNewswire/ -- Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery is pleased to announce that it has signed a contract with a GMP pharmaceutical FDA compliant formulation development company, Corealis Pharma, Inc. for the production of the phase I clinical supplies of KDM-1102, the Company's second lead therapeutic drug. The KDM-1102 drug is a new sublingual formulation of propanolol. The...
VANCOUVER, Sept. 16, 2011 /PRNewswire/ -- Global Health Ventures Inc. (OTCBB: GHLV), a specialty pharmaceutical company with a focus on sublingual drug delivery, is pleased to announce that CEO Dr. Hassan Salari will introduce the company to BetterInvesting National Convention participants in a corporate presentation at 1:20 p.m. on Saturday, Sept. 17. Dr. Salari will discuss the company's Sublingual Drug Delivery System and the company's first product in clinical trials, X-Excite, along...
NEW YORK, Aug. 8, 2011 /PRNewswire/ -- Global Health Ventures Inc. (OTCBB: GHLV), a specialty pharmaceutical company with focus on sublingual drug delivery announced today that their August 4th RetailInvestorConferences.com presentation by Dr. Hassan Salari PhD, Chairman and CEO, is available for on-demand viewing. LINK: www.retailinvestorconferences.com > Click the red "register/ watch event now" button. Their presentation will be available 24/7 for 90 days. Investors may download...
NEW YORK, Aug. 1, 2011 /PRNewswire/ -- Global Health Ventures Inc. (OTCBB: GHLV), a specialty pharmaceutical company with focus on sublingual drug delivery announced today that Dr. Hassan Salari PhD, Chairman and CEO will be presenting at RetailInvestorConferences.com. DATE: August 4, 2011TIME: 7:00pm EDTLINK: www.retailinvestorconferences.com>Click the red "register/ watch event now" button. This will be a live, interactive online event where investors are invited to ask the company...
WARREN, N.J., Feb. 22, 2011 /PRNewswire/ -- MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm® drug delivery technology, today announced that Reckitt Benckiser Pharmaceuticals Inc., a wholly-owned subsidiary of Reckitt Benckiser Group plc ("the Group") (LSE: RB), provided an update on U.S. market adoption of Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual film for the treatment of opioid dependence during its announcement of full-year 2010 financial results....
Immunotherapy given as pills or drops under the tongue is a safe and effective way to treat hayfever-like allergies caused by pollen and dust mites, according to a new Cochrane Systematic Review. The researchers say the approach is an attractive alternative to immunotherapy injections in children.Common treatments for hayfever-like symptoms caused by allergies include antihistamines and nasal corticosteroids. If these prove unsuccessful, doctors may recommend immunotherapy, a desensitisation...
ANTONY, France, October 14, 2010 /PRNewswire-FirstCall/ -- EUR million 2009 09-Aug 2010 10-Sep EURm %Sales Var.% EURm %Sales Var.% Southern Europe(1) 26 68 9 29.2 70 12 Other EU countries(2) 10.3 27 20 10.6 25 3 Other markets 1.9 5 8 2.2 5 15 SLIT 30.5 79 16 34.7...
